Pavilizumab Prophylaxis for RSV Bronchiolitis: Recommendation

Palivizumab is a humanized monoclonal antibody directed to an epitope in the A antigenic site of the F protein of RSV. It is a composite of primarily human antibody sequences (95%) and murine antibody sequences (5%). Palivizumab provides both neutralizing and fusion-inhibitory activity against RSV, resulting in inhibition of RSV replication. Although resistant RSV strains have been isolated in laboratory experiments, no resistant clinical isolates have been identified at this time.

Her are some updates- UPDATE on RSV prophylaxis

The updated policy recommends that RSV prophylaxis be considered in:
  • infants and children younger than 2 years of age who have required medical therapy for CLD within the 6 months prior to the start of RSV season; patients with severe CLD may benefit from prophylaxis with palivizumab through 2 RSV seasons
  • infants born at or prior to 32 weeks gestation
  • infants born between 32 and 35 weeks gestation with known risk factors, such as birth within 6 months of RSV season, child care attendance, school-age siblings, exposure to environmental pollutants, airway abnormalities, or severe neuromuscular disease
  • infants and children younger than 2 years of age with hemodynamically significant CHD, particularly patients with pulmonary hypertension or cyanotic heart disease, and those who require medication for congestive heart failure.

Source – AAP through Medscape 

Please follow and like us:

Leave a Reply

Your email address will not be published. Required fields are marked *